Latest Share Purchase Plans News

Nimy Resources has successfully raised $4.88 million through an oversubscribed Share Purchase Plan, signaling strong investor confidence in its Western Australian gallium and rare earths projects.

Barton Gold Holdings has secured $15 million through an institutional placement led by Franklin Templeton, with a $2.5 million Share Purchase Plan opening to shareholders. The capital raise supports the company’s goal to commission Stage 1 production by the end of 2026 in South Australia’s Gawler Craton.

Hazer Group has made significant strides in commercialising its methane pyrolysis technology, advancing key partnerships and strengthening its intellectual property portfolio amid a tightening global graphite market.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Catapult Sports has launched a Share Purchase Plan (SPP) offering eligible shareholders in Australia and New Zealand the chance to buy shares at a discount, following a recent A$130 million institutional placement and its acquisition of IMPECT GmbH.

Catapult Sports has launched a Share Purchase Plan (SPP) offering eligible shareholders in Australia and New Zealand the chance to buy up to A$30,000 in shares at a discount, following a successful A$130 million institutional placement. The capital raise supports the recent acquisition of IMPECT GmbH and future strategic opportunities.

Theta Gold Mines has secured an additional US$6 million from cornerstone investors and converted outstanding convertible loans into shares and options, reinforcing its balance sheet as it advances the TGME Gold Project in South Africa.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Southern Palladium has raised A$20 million through a strategic share placement to accelerate its Bengwenyama PGM project, positioning the company for key milestones including a Final Investment Decision in 2026.

Jindalee Lithium has launched an options offer linked to its recent Share Purchase Plan and placements, aiming to incentivize shareholders and raise capital for its lithium development projects. The options carry an exercise price of $0.825 and expire in late 2028.

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.